There has been only a few reports regarding aripiprazole causing false positive urine amphetamine drug screens, exclusively on children accidently ingesting aripiprazole. Herein, we present the first reported case of a 40 year old woman affected by Bipolar I Disorder, treated with aripirazole at therapeutic oral dose ranging from 15 mg/day to 30 mg/day, in the context of a depressive episode with mixed and psychotic features, showing a false positive urine amphetamine drug screen. We document the relationship between aripiprazole-dose, plasma concentration and amphetamines values in toxicologic urine examinations over time. Awareness of potential false positive urine amphetamine drug screens during aripiprazole treatment can condition therapeutic choices and prevent legal implications.
Aripiprazole causing false positive urine amphetamine drug screen in an adult patient with bipolar disorder / V. Caricasole, G. Spagnolo, I. Di Bernardo, G. Cirnigliaro, E. Piccoli, B. Dell'Osso. - In: COMPREHENSIVE PSYCHIATRY. - ISSN 0010-440X. - 94(2019). [10.1016/j.comppsych.2019.152126]
Aripiprazole causing false positive urine amphetamine drug screen in an adult patient with bipolar disorder
V. CaricasolePrimo
;G. SpagnoloSecondo
;I. Di Bernardo;G. Cirnigliaro;E. PiccoliPenultimo
;B. Dell'OssoUltimo
2019
Abstract
There has been only a few reports regarding aripiprazole causing false positive urine amphetamine drug screens, exclusively on children accidently ingesting aripiprazole. Herein, we present the first reported case of a 40 year old woman affected by Bipolar I Disorder, treated with aripirazole at therapeutic oral dose ranging from 15 mg/day to 30 mg/day, in the context of a depressive episode with mixed and psychotic features, showing a false positive urine amphetamine drug screen. We document the relationship between aripiprazole-dose, plasma concentration and amphetamines values in toxicologic urine examinations over time. Awareness of potential false positive urine amphetamine drug screens during aripiprazole treatment can condition therapeutic choices and prevent legal implications.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0010440X19300495-main.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
427.33 kB
Formato
Adobe PDF
|
427.33 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.